We therefore conducted the current retrospective study to compare upfront RT combined with icotinib to icotinib alone as first-line therapies for patients with EGFR-mutant NSCLC and BM as well as to identify prognostic factors that could be used to tailor treatment strategies. Here, EGFR is linked to non-small cell lung carcinoma.